Back to search

Article

Phase 1 Study of Safety, Reactogenicity, and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate Administered as Inhalation Boost in SARS-CoV-2 Immunized Adults

2025-10-08

Abstract excerpt

<h4>Background</h4> Existing parenteral SARS-CoV-2 vaccines protect against severe disease but do not reliably prevent infection or reinfection. Inhaled vaccines may elicit localized immunity in the respiratory tract, a principal entry site for SARS-CoV-2. <h4>Methods</h4> In this investigator-initiated, single-center, open-label phase 1 trial ( NCT05226390 , ClinicalTrials.gov ), 23 healthy adults previously im...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a865a278-0102-598a-aa33-d780f807b1fc
DOI
10.1101/2025.10.07.25337492
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Phase 1 Study of Safety, Reactogenicity, and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate Administered as Inhalation Boost in SARS-CoV-2 Immunized AdultsDOI 10.1101/2025.10.07.25337492
An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccineSemantic proximity
Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled TrialSemantic proximity
Mucosal and systemic responses to SARS-CoV-2 vaccination in infection naïve and experienced individualsSemantic proximity
Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccinationSemantic proximity
Cohort Profile: The Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 vaccines (ENFORCE)Semantic proximity
The efficacy, safety and immunogenicity Nanocovax: results of a randomized, double-blind, placebo-controlled Phase 3 trialSemantic proximity
Safety and Immunogenicity of CpG 1018 and Aluminium Hydroxide-Adjuvanted SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901: A Large-Scale Double-Blind, Randomised, Placebo-Controlled Phase 2 TrialSemantic proximity
A Phase I, Prospective, Randomized, Open-labeled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2 Vaccine in AdultsSemantic proximity
Protection of Hamsters Challenged with SARS-CoV-2 after Two Doses of MVC-COV1901 Vaccine Followed by a Single Intranasal Booster with Nanoemulsion Adjuvanted S-2P VaccineSemantic proximity
Efficacy of Heterologous Boosting Using Recombinant SARS-CoV-2 Fusion Protein Vaccine: A Randomized, Double-Blind and Placebo-Controlled Phase III TrialSemantic proximity
Cellular immune response to SARS-CoV-2 infection in humans: a systematic reviewSemantic proximity
A Phase I, Prospective, Randomized, Open-Labeled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2 Vaccine in AdultsSemantic proximity
Select a neighboring publication to make it the new centre.